Last updated on April 2018

Phase III Radium 223 mCRPC-PEACE III

Brief description of study

The objective of this randomized phase III open label trial is to assess if upfront combination of enzalutamide and Ra223 improves radiological progression-free survival compared to enzalutamide single agent in asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastatic to bone.

Clinical Study Identifier: NCT02194842

Find a site near you

Start Over


Copenhagen, Denmark
  Connect »